Denali Therapeutics Inc (DNLI) — Capital Reinvestment Ratio
Latest as of December 2020:
0.00x
Denali Therapeutics Inc (DNLI) has a Capital Reinvestment Ratio of 0.00x as of December 2020, meaning it reinvests 0% of its operating cash flow ($513.91 Million) in capital expenditures ($1.19 Million). See DNLI cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.00x
Capex / Operating Cash Flow
Operating Cash Flow
$513.91 Million
USD
Capital Expenditures
$1.19 Million
USD
Data as of
Dec 2020
Most recent filing
Denali Therapeutics Inc Capital Reinvestment Ratio (2018–2020)
This chart tracks Denali Therapeutics Inc's Capital Reinvestment Ratio across 2 annual periods.
Annual Capital Reinvestment Ratio for Denali Therapeutics Inc (2018–2020)
Year-by-year Capital Reinvestment Ratio for Denali Therapeutics Inc from 2018 to 2020. For live market cap and broader valuation context, see DNLI stock market capitalisation.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2020 | 0.01x | $416.15 Million | $3.10 Million | ▼ -89.0% |
| 2018 | 0.07x | $50.12 Million | $3.39 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow